NO20073078L - Transplantasjon av humane nerveceller for behandling av tilstander med nervedegenerering - Google Patents

Transplantasjon av humane nerveceller for behandling av tilstander med nervedegenerering

Info

Publication number
NO20073078L
NO20073078L NO20073078A NO20073078A NO20073078L NO 20073078 L NO20073078 L NO 20073078L NO 20073078 A NO20073078 A NO 20073078A NO 20073078 A NO20073078 A NO 20073078A NO 20073078 L NO20073078 L NO 20073078L
Authority
NO
Norway
Prior art keywords
neurons
cells
transplantation
stem cells
region
Prior art date
Application number
NO20073078A
Other languages
English (en)
Other versions
NO340914B1 (no
Inventor
Martin Marsala
Karl K Johe
Thomas G Hazel
Osamu Kakinohama
Vassilis Koliatsos
Jun Yan
Paul J Reier
Margaret J Velardo
Original Assignee
Neuralstem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuralstem Inc filed Critical Neuralstem Inc
Publication of NO20073078L publication Critical patent/NO20073078L/no
Publication of NO340914B1 publication Critical patent/NO340914B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/113—Acidic fibroblast growth factor (aFGF, FGF-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/148—Transforming growth factor alpha [TGF-a]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)

Abstract

En fremgangsmåte for behandling av neurodegenerative tilstander tilveiebringes. Nervestamceller kan implanteres i et område med neurondegenerasjon og/eller i et område fjernt fra et område med neurondegenerasjon. Fremgangsmåtene kan omfatte isolering av nervestamceller fra områder hvor spesifikke typer av neuroner som tilsvarer neuronene som skal erstattes dannes. Fremgangsmåtene kan omfatte isolering av nervestamceller som utskiller vekstfaktorer som påvirker vekst og/eller regenerasjon av spesifikke typer av neuroner. I foreliggende oppfinnelse beskriver vi en fremgangsmåte for behandling av slike forstyrrelser, innbefattet flere neurodegenerative forstyrrelser som skyldes mangel på celler som danner spesielle neurotransmittere i nervenettverket, ved transplantasjon av eksogent dyrkede og ekspanderte neurale progenitorceller som etter transplantering i et nervevev differensierer til neuroner som kan integreres og som danner neurotransmittere i tilstrekkelige mengder, og på en måte som er tilstrekkelig til å overvinne symptomene forbundet med neurodegenerasjonen.
NO20073078A 2004-11-17 2007-06-15 In vitro fremgangsmåte for fremstilling av en populasjon av nervestamceller som er i stand til å generere nevroner i en mottakers ryggmarg. NO340914B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62922004P 2004-11-17 2004-11-17
PCT/US2005/041631 WO2006055685A2 (en) 2004-11-17 2005-11-17 Transplantation of human neural cells for treatment of neurodegenerative conditions

Publications (2)

Publication Number Publication Date
NO20073078L true NO20073078L (no) 2007-08-16
NO340914B1 NO340914B1 (no) 2017-07-10

Family

ID=36407743

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073078A NO340914B1 (no) 2004-11-17 2007-06-15 In vitro fremgangsmåte for fremstilling av en populasjon av nervestamceller som er i stand til å generere nevroner i en mottakers ryggmarg.

Country Status (13)

Country Link
US (6) US7691629B2 (no)
EP (2) EP2913393B8 (no)
JP (3) JP5424559B2 (no)
KR (2) KR101429284B1 (no)
CN (2) CN101084303A (no)
ES (1) ES2537004T3 (no)
HK (1) HK1202238A1 (no)
IL (2) IL183092A (no)
IN (1) IN2014CN03629A (no)
NO (1) NO340914B1 (no)
PH (1) PH12015501195A1 (no)
RU (2) RU2434636C2 (no)
WO (1) WO2006055685A2 (no)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838292B1 (en) 2001-03-29 2010-11-23 University Of Louisville Research Foundation, Inc. Methods for obtaining adult human olfactory progenitor cells
US9572840B2 (en) 2003-06-27 2017-02-21 DePuy Synthes Products, Inc. Regeneration and repair of neural tissue using postpartum-derived cells
US9592258B2 (en) 2003-06-27 2017-03-14 DePuy Synthes Products, Inc. Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
US8491883B2 (en) * 2003-06-27 2013-07-23 Advanced Technologies And Regenerative Medicine, Llc Treatment of amyotrophic lateral sclerosis using umbilical derived cells
ES2537004T3 (es) 2004-11-17 2015-06-01 Neuralstem, Inc. Trasplante de células neurales humanas para el tratamiento de afecciones neurodegenerativas
CN101605552A (zh) 2005-03-07 2009-12-16 桑比欧公司 神经元前体细胞用于治疗中枢神经系统损伤的用途
GB0822246D0 (en) 2008-12-05 2009-01-14 Reneuron Ltd Composition
CN102387807A (zh) 2008-12-19 2012-03-21 先进科技及再生医学有限责任公司 肺部疾病和病症的治疗
EP2379087B1 (en) * 2008-12-19 2014-08-20 DePuy Synthes Products, LLC Umbilical cord tissue derived cells for treating neuropathic pain and spasticity
GB0902034D0 (en) * 2009-02-06 2009-03-11 Reneuron Ltd Method
US10386360B2 (en) 2009-03-13 2019-08-20 University Of Central Florida Research Foundation, Inc. Bio-microelectromechanical system transducer and associated methods
US8722034B2 (en) 2009-03-26 2014-05-13 Depuy Synthes Products Llc hUTC as therapy for Alzheimer's disease
US9163216B1 (en) 2009-04-23 2015-10-20 University Of Central Florida Research Foundation, Inc. Method for culturing skeletal muscle for tissue engineering
US8815584B1 (en) 2009-04-23 2014-08-26 University Of Central Florida Research Foundation, Inc. Method of co-culturing mammalian muscle cells and motoneurons
US8828721B1 (en) 2009-05-28 2014-09-09 University Of Central Florida Research Foundation, Inc. Method of myelinating isolated motoneurons
US9404140B1 (en) 2009-11-03 2016-08-02 The University Of Central Florida Research Foundation, Inc. Patterned cardiomyocyte culture on microelectrode array
CA2788905A1 (en) 2010-02-05 2011-08-11 University Of Central Florida Research Foundation, Inc. Model and methods for identifying points of action in electrically active cells
EP2585171B1 (en) 2010-04-23 2018-12-26 University Of Central Florida Research Foundation, Inc. Formation of neuromuscular junctions in a defined system
US9540611B2 (en) * 2010-07-28 2017-01-10 Neuralstem, Inc. Methods for treating and/or reversing neurodegenerative diseases and/or disorders
US9498554B2 (en) 2012-07-24 2016-11-22 S.C. Johnson & Son, Inc. Dispensing device
US10357517B1 (en) 2012-10-01 2019-07-23 University Of South Florida Methods of treating epilepsy using neural stem cells that express nanog, SSEA-4, OCT-4, MIR-34B, MIR-34C and MIR-592
RU2515475C1 (ru) * 2012-11-15 2014-05-10 Федеральное государственное бюджетное учреждение науки ИНСТИТУТ ЦИТОЛОГИИ РОССИЙСКОЙ АКАДЕМИИ НАУК Способ стимуляции образования децидуальной оболочки эндометрия в эксперименте
US10694747B2 (en) 2012-11-21 2020-06-30 S. C. Johnson & Son, Inc. Dispenser comprising only one single hinge
US20150369791A1 (en) 2013-01-30 2015-12-24 University Of Central Florida Research Foundation, Inc. Devices and systems for mimicking heart function
WO2014138003A1 (en) * 2013-03-04 2014-09-12 Neuralstem, Inc. Compositions comprising an immunosuppressive drug and/or neural stem cells and methods of using same for the treatment of neurodegenerative diseases and/or disorders
EP3498824A1 (en) 2013-04-26 2019-06-19 Memorial Sloan-Kettering Cancer Center Cortical interneurons and other neuronal cells produced by the directed differentiation of pluripotent and multipotent cells
CN104278008B (zh) 2013-07-12 2020-08-21 北京宏冠再生医学科技有限公司 一种通过小分子化合物处理来制备多潜能干细胞的方法、试剂盒和用途
KR101675123B1 (ko) * 2014-06-27 2016-11-14 연세대학교 산학협력단 Psa-ncam-양성 신경전구세포를 유효성분으로 포함하는 허혈성 질환 또는 신경염증 질환 치료용 조성물
RU2745300C2 (ru) * 2014-06-27 2021-03-23 Анджиокрин Биосайенс, Инк. Клетки нервной системы, экспрессирующие e4orf1 аденовируса, и способы их получения и применения
US10935541B2 (en) 2014-08-07 2021-03-02 University Of Central Florida Research Foundation, Inc. Devices and methods comprising neuromuscular junctions
MX2017005186A (es) 2014-10-20 2017-07-26 Neuralstem Inc Celulas madre neurales estables que comprenden un polinucleótido exógeno que codifica un factor de crecimiento y métodos de uso de las mismas.
US10286009B2 (en) * 2015-05-16 2019-05-14 Asterias Biotherapeutics, Inc. Pluripotent stem cell-derived oligodendrocyte progenitor cells for the treatment of spinal cord injury
JP6780870B2 (ja) 2015-08-13 2020-11-04 北昊干細胞与再生医学研究院有限公司Ｂｅｉｈａｏ Ｓｔｅｍ Ｃｅｌｌ Ａｎｄ Ｒｅｇｅｎｅｒａｔｉｖｅ Ｍｅｄｉｃｉｎｅ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ Ｃｏ．， Ｌｔｄ． 誘導された拡張された多能性幹細胞、作製方法および使用方法
US20190282624A1 (en) 2015-11-30 2019-09-19 Beihao Stem Cell And Regenerative Medicine Research Institute Co., Ltd. Improved methods for reprograming non-pluripotent cells into pluripotent stem cells
EP3412296A4 (en) * 2016-02-05 2019-09-11 Kyungpook National University Industry-Academic Cooperation Foundation PHARMACEUTICAL COMPOSITION COMPRISING STEM CELLS IN WHICH A VASCULAR ENDOTHELIUM GROWTH FACTOR IS OVEREXPRESSED AS AN ACTIVE INGREDIENT TO PREVENT OR TREAT NEURODEGENERATIVE DISEASE
WO2017173064A1 (en) 2016-03-30 2017-10-05 Asterias Biotherapeutics, Inc. Oligodendrocyte progenitor cell compositions
FR3058892B1 (fr) * 2016-11-23 2021-04-09 Univ Bordeaux Unite de tissu neural et utilisation d'une telle unite pour l'implantation dans le systeme nerveux d'un mammifere
CN106619722A (zh) * 2016-12-05 2017-05-10 上海安集协康生物技术股份有限公司 一种治疗脑部损伤类疾病的神经干细胞注射液
JP6500051B2 (ja) * 2017-03-17 2019-04-10 哲丸 村田 組織処理方法
WO2018218480A1 (en) 2017-05-31 2018-12-06 Beihao Stem Cell And Regenerative Medicine Research Institute Co., Ltd. Methods for chemically induced lineage reprogramming
SG11202107732XA (en) 2019-01-23 2021-08-30 Asterias Biotherapeutics Inc Dorsally-derived oligodendrocyte progenitor cells from human pluripotent stem cells
CN111494422B (zh) * 2019-01-29 2022-04-29 中国科学院遗传与发育生物学研究所 治疗脊髓损伤的产品及其应用
EP4082445A4 (en) * 2019-12-27 2024-07-17 Rainbow Inc INTEGRATED SYSTEM FOR CELL-FREE INTRACRANIAL DELIVERY
CN115166260B (zh) * 2022-07-11 2023-06-13 东南大学 血浆脑细胞来源外泌体中维生素d结合蛋白在诊断抑郁症中的应用

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0233838A3 (en) 1986-02-04 1990-01-31 Incyte Pharmaceuticals, Inc. Neurite-promoting factor and process for the manufacture thereof
US4753635A (en) 1986-05-23 1988-06-28 Jacqueline Sagen Inducing analgesia by implantation of cells releasing neuroactive substances
NZ226750A (en) 1987-10-29 1990-09-26 Amrad Corp Ltd Immortalisation of neural precursor cells by introducing a retrovirus vector containing a myc-oncogene
WO1990001541A1 (en) 1988-08-04 1990-02-22 Amrad Corporation Limited In vitro propagation of embryonic stem cells
US5082670A (en) 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
US4980174A (en) 1988-12-23 1990-12-25 Jacqueline Sagen Method for alleviating depression
AU6174490A (en) 1989-08-04 1991-03-11 Board Of Regents, The University Of Texas System Methods and compositions; purified preparation of neural progenitor regulatory factor
US5411883A (en) 1989-12-26 1995-05-02 Somatix Therapy Corporation Proliferated neuron progenitor cell product and process
WO1991009936A1 (en) 1989-12-26 1991-07-11 Hana Biologics, Inc. Proliferated neuron progenitor cell product and process
US5196315A (en) 1990-05-01 1993-03-23 The Johns Hopkins University Human neuronal cell line
US5612211A (en) 1990-06-08 1997-03-18 New York University Stimulation, production and culturing of hematopoietic progenitor cells by fibroblast growth factors
AU665012B2 (en) 1991-07-08 1995-12-14 Neurospheres Holdings Ltd Novel growth factor-responsive progenitor cells which can be proliferated (in vitro)
US6071889A (en) 1991-07-08 2000-06-06 Neurospheres Holdings Ltd. In vivo genetic modification of growth factor-responsive neural precursor cells
US6399369B1 (en) 1991-07-08 2002-06-04 Neurospheres Holdings Ltd. Multipotent neural stem cell cDNA libraries
US6294346B1 (en) 1991-07-08 2001-09-25 Neurospheres Holdings, Ltd. Use of multipotent neural stem cells and their progeny for the screening of drugs and other biological agents
US5851832A (en) 1991-07-08 1998-12-22 Neurospheres, Ltd. In vitro growth and proliferation of multipotent neural stem cells and their progeny
US7361505B1 (en) 1991-07-08 2008-04-22 Neurospheres Holdings Ltd. Multipotent neural stem cell compositions
US5981165A (en) * 1991-07-08 1999-11-09 Neurospheres Holdings Ltd. In vitro induction of dopaminergic cells
US6497872B1 (en) * 1991-07-08 2002-12-24 Neurospheres Holdings Ltd. Neural transplantation using proliferated multipotent neural stem cells and their progeny
US5750376A (en) * 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
AU675409B2 (en) * 1991-07-10 1997-02-06 Regeneron Pharmaceuticals, Inc. Methods of treatment of motor neuron diseases using members of the BDNF/NT-3/NGF family of molecules
US5175103A (en) 1991-10-21 1992-12-29 Trustees Of University Of Pennsylvania Preparation of pure cultures of post-mitotic human neurons
DE69228949T2 (de) 1991-11-22 1999-09-16 Auckland Uniservices Ltd., Auckland Tgf-beta zur verbesserung der regeneration von neuronalem gewebe
US5849553A (en) 1992-07-27 1998-12-15 California Institute Of Technology Mammalian multipotent neural stem cells
AU678988B2 (en) * 1992-07-27 1997-06-19 California Institute Of Technology Mammalian multipotent neural stem cells
US5693482A (en) 1992-07-27 1997-12-02 California Institute Of Technology Neural chest stem cell assay
US5589376A (en) 1992-07-27 1996-12-31 California Institute Of Technology Mammalian neural crest stem cells
WO1994003199A1 (en) 1992-08-04 1994-02-17 Regeneron Pharmaceuticals, Inc. Method of enhancing differentiation and survival of neuronal precursor cells
WO1994004675A2 (en) 1992-08-19 1994-03-03 Richard Kroczek Dna sequence encoding a novel member of the steroid and thyroid hormone receptor family
EP1298202B1 (en) 1992-10-28 2010-10-06 NeuroSpheres Holdings Ltd. Biological factors and neural stem cells
DK0728194T3 (da) 1993-11-09 2003-04-22 Neurospheres Holdings Ltd In situ modifikation og manipulation af stamceller fra centralnervesystemet.
ES2167461T3 (es) 1994-09-23 2002-05-16 Neurospheres Holdings Ltd Modelos in vitro de funcion y disfuncion del sistema nervioso central.
WO1996015226A1 (en) 1994-11-14 1996-05-23 Neurospheres Holdings Ltd. Regulation of neural stem cell proliferation
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5735505A (en) * 1995-04-03 1998-04-07 Data Connections, Inc. Cable pulley device and method
US5753505A (en) 1995-07-06 1998-05-19 Emory University Neuronal progenitor cells and uses thereof
US5770414A (en) 1996-02-20 1998-06-23 The Regents Of The University Of California Regulatable retrovirus system for genetic modification of cells
US5753506A (en) 1996-05-23 1998-05-19 Cns Stem Cell Technology, Inc. Isolation propagation and directed differentiation of stem cells from embryonic and adult central nervous system of mammals
JP3467154B2 (ja) * 1996-10-14 2003-11-17 パロマ工業株式会社 吸収式空調機
AU7258098A (en) 1997-04-24 1998-11-13 California Institute Of Technology Methods for differentiating neural stem cells
KR20060002033A (ko) 1997-07-04 2006-01-06 유니버시티 오브 유타 리서치 파운데이션 계통이 예정된 신경세포 전구체
US5968829A (en) 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
US5932473A (en) * 1997-09-30 1999-08-03 Becton Dickinson And Company Preparation of a cell culture substrate coated with poly-D-lysine
US5958767A (en) 1998-08-14 1999-09-28 The Children's Medical Center Corp. Engraftable human neural stem cells
WO2000017323A1 (en) * 1998-09-22 2000-03-30 Neuralstem Biopharmaceuticals, Ltd. Stable neural stem cell lines
US6284539B1 (en) 1998-10-09 2001-09-04 Neuralstem Biopharmaceuticals, Ltd. Method for generating dopaminergic cells derived from neural precursors
US6531464B1 (en) 1999-12-07 2003-03-11 Inotek Pharmaceutical Corporation Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives
HN2001000224A (es) 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
DE60217090T2 (de) 2001-04-23 2007-07-12 The Trustees Of The University Of Pennsylvania Amyloid plaque aggregationshemmer und diagnostische bilderzeugungsmittel
EP1572879A4 (en) 2001-06-22 2006-11-15 Univ Texas METHOD FOR PRODUCING REGION-SPECIFIC NEURONS FROM HUMAN NEURONAL STEM CELLS
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
WO2003046141A2 (en) * 2001-11-26 2003-06-05 Advanced Cell Technology, Inc. Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells
WO2004072264A2 (en) * 2003-02-12 2004-08-26 Johns Hopkins University School Of Medicine Fate determination by hes 1 in hematopoietic stem-progenitor cells and uses thereof
ES2537004T3 (es) 2004-11-17 2015-06-01 Neuralstem, Inc. Trasplante de células neurales humanas para el tratamiento de afecciones neurodegenerativas
US20120107284A1 (en) 2006-06-30 2012-05-03 Elena Kozlova Stem cells for transplantation and methods for production thereof
US9540611B2 (en) * 2010-07-28 2017-01-10 Neuralstem, Inc. Methods for treating and/or reversing neurodegenerative diseases and/or disorders

Also Published As

Publication number Publication date
RU2434636C2 (ru) 2011-11-27
US20100239541A1 (en) 2010-09-23
US20100055075A1 (en) 2010-03-04
IL183092A (en) 2011-11-30
US7691629B2 (en) 2010-04-06
CN104042629A (zh) 2014-09-17
US8236299B2 (en) 2012-08-07
JP5805551B2 (ja) 2015-11-04
JP2008520687A (ja) 2008-06-19
JP5424559B2 (ja) 2014-02-26
EP2913393B1 (en) 2020-01-08
IN2014CN03629A (no) 2015-09-04
EP1814979A4 (en) 2008-09-03
KR101505347B1 (ko) 2015-03-23
US10286010B2 (en) 2019-05-14
JP5981526B2 (ja) 2016-08-31
US8460651B2 (en) 2013-06-11
HK1202238A1 (en) 2015-09-25
CN101084303A (zh) 2007-12-05
WO2006055685A3 (en) 2007-03-15
ES2537004T3 (es) 2015-06-01
NO340914B1 (no) 2017-07-10
PH12015501195B1 (en) 2015-12-07
JP2012095667A (ja) 2012-05-24
EP1814979B1 (en) 2015-04-08
IL204356A (en) 2011-09-27
RU2007122507A (ru) 2008-12-27
EP2913393A1 (en) 2015-09-02
RU2011131830A (ru) 2013-02-10
US20130251686A1 (en) 2013-09-26
KR101429284B1 (ko) 2014-08-11
KR20130092634A (ko) 2013-08-20
US9220730B2 (en) 2015-12-29
EP2913393B8 (en) 2020-02-26
KR20070109979A (ko) 2007-11-15
US9744194B2 (en) 2017-08-29
US20170333484A1 (en) 2017-11-23
US20160228471A1 (en) 2016-08-11
WO2006055685A2 (en) 2006-05-26
EP1814979A2 (en) 2007-08-08
IL183092A0 (en) 2007-09-20
US20060141622A1 (en) 2006-06-29
PH12015501195A1 (en) 2015-12-07
JP2015062735A (ja) 2015-04-09

Similar Documents

Publication Publication Date Title
NO20073078L (no) Transplantasjon av humane nerveceller for behandling av tilstander med nervedegenerering
Dunnett et al. Challenges for taking primary and stem cells into clinical neurotransplantation trials for neurodegenerative disease
IL262440B2 (en) A method for preparing retinal tissue
Bernal et al. Neural stem cells as therapeutic agents for age‐related brain repair
GB2452667A (en) Efficient generation of neural progenitors, neurons and dopaminergic neurons from human embryonic stem cells
Cebria et al. Rebuilding a planarian: from early signaling to final shape
WO2004018655A3 (en) Method for culturing stem cells
MX2011007567A (es) Metodos para la inhibicion de la neurodegeneracion.
MY148938A (en) Method of converting feedstocks coming from renewable sources into high-quality gas-oil fuel bases
WO2007025177A3 (en) Neurogenesis by muscarinic receptor modulation
WO2021076883A3 (en) Muscle regeneration and growth
MX2021005518A (es) Modelos animales, métodos de detección y métodos de tratamiento para enfermedades o trastornos intraoculares.
WO2005079250A3 (en) Purines are self-renewal signals for neural stem cells, and purine receptor antagonists promote neuronal and glial differentiation therefrom
MX2018009189A (es) Compuestos de anillo de siete miembros de pirimidina.
MY168084A (en) Methods for treating and/or reversing neurodegenerative diseases and/or disorders
Ben M’Barek et al. Cell therapy for retinal dystrophies: from cell suspension formulation to complex retinal tissue bioengineering
WO2007080606A9 (en) Process for increased patchulol content in essential oil of pogostemon cablin
WO2004053084A3 (en) Dopaminergic neurons differentiated from embryonic cells for treating neurodegenerative diseases
WO2007092535A3 (en) 4-acylaminopyridine derivative mediated neurogenesis
Mustafa et al. Overcoming phenolic accumulation of date palm in vitro culture using-tochopherol and cold pre-treatment
Ng et al. Development of treated palm oil mill effluent (POME) culture medium for plant tissue culture of Hemianthus callitrichoides
WO2007031556A3 (en) Means and methods to enhance the production of vinblastine and vincristine in catharanthus roseus
Chavarría et al. Early neural cell death is an extensive, dynamic process in the embryonic chick and mouse retina
PH12017500998A1 (en) Treatment of ocular conditions using progenitor cells
MX2021001264A (es) Métodos para tratar la vejiga hiperactiva con el uso de trospio.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees